High-fat/high-cholesterol diet promotes a S1P receptor-mediated antiapoptotic activity for VLDL

Journal of Lipid Research

Volumn 48, Issue 4, 2007, Pages 806-815

  Mihovilovic, Mirta ^a   Robinette, Jennifer B ^a   DeKroon, Robert M ^a   Sullivan, Patrick M ^a   Strittmatter, Warren J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apolipoprotein E; Atherosclerosis; Endothelial cells; High density lipoprotein; Sphingosine 1 phosphate; Very low density lipoprotein

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CASPASE 3; CASPASE 7; HIGH DENSITY LIPOPROTEIN; RECEPTOR BLOCKING AGENT; SMALL INTERFERING RNA; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; VPC 23019;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; DIETARY INTAKE; ELECTROPHORESIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING;

ANIMALS; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOPTOSIS; CASPASES; CELL SURVIVAL; CHOLESTEROL; DIET; DIETARY FATS; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MICE; MICE, TRANSGENIC; RECEPTORS, LYSOSPHINGOLIPID;

EID: 34147126295     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M600201-JLR200     Document Type: Article

References (37)

1. Fan, J., and T. Watanabe. 2003. Inflammatory reactions in the pathogenesis of atherosclerosis. J. Atheroscler. Thromb. 10: 63-71.
2. Rader, D. J., and K. A. Dugi. 2000. The endothelium and lipoproteins: insights from recent cell biology and animal studies. Semin. Thromb. Hemost. 26: 521-528.
3. De Geest, B., Z. Zhao, D. Collen, and P. Holvoet. 1997. Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. Circulation. 96: 4349-4356.
4. Karpe, F., G. Steiner, K. Uffelman, T. Olivecrona, and A. Hamsten. 1994. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 106: 83-97.
5. Weisgraber, K. H., T. L. Innerarity, S. C. Rall, Jr., and R. W. Mahley. 1990. Atherogenic lipoproteins resulting from genetic defects of apolipoproteins B and E. Ann. N. Y. Acad. Sci. 598: 37-48.
6. Nofer, J. R., B. Levkau, I. Wolinska, R. Junker, M. Fobker, A. von Eckardstein, U. Seedorf, and G. Assmann. 2001. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J. Biol. Chem. 276: 34480-34485.
7. 3. J. Clin. Invest. 113: 569-581.
8. Kimura, T., K. Sato, E. Malchinkhuu, H. Tomura, K. Tamama, A. Kuwabara, M. Murakami, and F. Okajima. 2003. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol. 23: 1283-1288.
9. DeKroon, R. M., M. Mihovilovic, Z. V. Goodger, J. B. Robinette, P. M. Sullivan, A. M. Saunders, and W. J. Strittmatter. 2003. ApoE genotype-specific inhibition of apoptosis. J. Lipid. Res. 44: 1566-1573.
10. Herz, J., J. L. Goldstein, D. K. Strickland, Y. K. Ho, and M. S. Brown. 1991. 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. J. Biol. Chem. 266: 21232-21238.
11. Willnow, T. E., A. Rohlmann, J. Horton, H. Otani, J. R. Braun, R. E. Hammer, and J. Herz. 1996. RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptors. EMBO J. 15: 2632-2639.
12. Knouff, C., M. E. Hinsdale, H. Mezdour, M. K. Altenburg, M. Watanabe, S. H. Quarfordt, P. M. Sullivan, and N. Maeda. 1999. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J. Clin. Invest. 103: 1579-1586.
13. Sullivan, P. M., H. Mezdour, Y. Aratani, C. Knouff, J. Najib, R. L. Reddick, S. H. Quarfordt, and N. Maeda. 1997. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J. Biol. Chem. 272: 17972-17980.
14. Paigen, B., A. Morrow, P. A. Holmes, D. Mitchell, and R. A. Williams. 1987. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 68: 231-240.
15. Kimura, T., T. Watanabe, K. Sato, J. Kon, H. Tomura, K. Tamama, A. Kuwabara, T. Kanda, I. Kobayashi, H. Ohta, et al. 2000. Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-1 and Edg-3. Biochem. J. 1: 71-76.
16. 3 receptors. Drug News Perspect. 17: 365-382.
17. Davis, M. D., J. J. Clemens, T. L. Macdonald, and K. R. Lynch. 2005. Sphingosine 1-phosphate analogs as receptor antagonists. J. Biol. Chem. 280: 9833-9841.
18. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 3: 1345-1353.
19. Ordovas, J. M. 1998. Fast ultracentrifugation methods for the separation of plasma lipoproteins. Methods Mol. Biol. 110: 93-103.
20. Mihovilovic, M., and J. Butterworth-Robinette. 2001. Thymic epithelial cells expressing transcripts encoding α-3, α-5 and β-4 subunits of acetylcholine receptors respond to cholinergic agents and express choline acetyl transferase. J. Neuroimmunol. 117: 58-67.
21. Bielawski, J., Z. M. Szulc, Y. A. Hannun, and A. Bielawska. 2006. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods. 39: 82-91.
22. Fidge, N. H., and P. J. McCullagh. 1981. Studies on the apoproteins of rat lymph chylomicrons: characterization and metabolism of a new chylomicron-associated apoprotein. J. Lipid Res. 22: 138-146.
23. Glickman, R. M., and P. H. Green. 1977. The intestine as a source of apolipoprotein A1. Proc. Natl. Acad. Sci. USA. 74: 2569-2573.
24. Imaizumi, K., M. Fainaru, and R. J. Havel. 1978. Composition of proteins of mesenteric lymph chylomicrons in the rat and alterations produced upon exposure of chylomicrons to blood serum and serum proteins. J. Lipid. Res. 19: 712-722.
25. Nuñez, G., M. A. Benedict, Y. Hu, and N. Inohara. 1998. Caspases: the proteases of the apoptotic pathway. Oncogene. 17: 3237-3245.
26. Rosen, H., and J. Liao. 2003. Sphingosine 1-phosphate pathway therapeutics: a lipid ligand-receptor paradigm. Curr. Opin. Chem. Biol. 7: 461-468.
27. DeKroon, R., J. B. Robinette, A. B. Hjelmeland, E. Wiggins, M. Blackwell, M. Mihovilovic, M. Fujii, J. York, J. Hart, C. Kontos, et al. 2006. ApoE4-VLDL inhibits the HDL-activated phosphatidylinositol 3-kinase/Akt pathway via the phosphoinositol phosphatase SHIP2. Circ. Res. 99: 829-836.
28. Calvo, D., D. Gomez-Coronado, M. A. Lasuncion, and M. A. Vega. 1997. CLA-1 is an 85-kD plasma membrane glycoprotein that acts as a high-affinity receptor for both native (HDL, LDL, and VLDL) and modified (OxLDL and AcLDL) lipoproteins. Arterioscler. Thromb. Vasc. Biol. 17: 2341-2349.
29. Calvo, D., D. Gomez-Coronado, Y. Suarez, M. A. Lasuncion, and M. A. Vega. 1998. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J. Lipid. Res. 39: 777-788.
30. Englyst, N. A., J. M. Taube, T. J. Aitman, T. P. Baglin, and C. D. Byrne. 2003. A novel role for CD36 in VLDL-enhanced platelet activation. Diabetes. 52: 1248-1255.
31. Al-Haideri, M., I. J. Goldberg, N. F. Galeano, A. Gleeson, T. Vogel, M. Gorecki, S. L. Sturley, and R. J. Deckelbaum. 1997. Heparan sulfate proteoglycan-mediated uptake of apolipoprotein E-triglyceride-rich lipoprotein particles: a major pathway at physiological particle concentrations. Biochemistry. 36: 12766-12772.
32. Fuki, I. V., N. Blanchard, W. Jin, D. H. Marchadier, J. S. Millar, J. M. Glick, and D. J. Rader. 2003. Endogenously produced endothelial lipase enhances binding and cellular processing of plasma lipoproteins via heparan sulfate proteoglycan-mediated pathway. J. Biol. Chem. 278: 34331-34338.
33. Olsson, U., G. Ostergren-Lunden, and J. Moses. 2001. Glycosaminoglycan- lipoprotein interaction. Glycoconj. J. 18: 789-797.
34. Tamama, K., J. Kon, K. Sato, H. Tomura, A. Kuwabara, T. Kimura, T. Kanda, H. Ohta, M. Ui, I. Kobayashi, et al. 2001. Extracellular mechanism through the Edg family of receptors might be responsible for sphingosine-1-phosphate-induced regulation of DNA synthesis and migration of rat aortic smooth-muscle cells. Biochem. J. 353: 139-146.
35. Siess, W. 2002. Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim. Biophys. Acta. 1582: 204-215.
36. Yatomi, Y. 2006. Sphingosine 1-phosphate in vascular biology: possible therapeutic strategies to control vascular diseases. Curr. Pharm. Des. 12: 575-587.
37. Gardell, S. E., A. E. Dubin, and J. Chun. 2006. Emerging medicinal roles for lysophospholipid signaling. Trends Mol. Med. 12: 65-75.